Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty math, Captisol shipment volumes, and partner milestone clauses turn each Ligand Pharmaceuticals filing into a maze of tables and footnotes. If you have ever searched hundreds of pages just to confirm which partner drove last quarter’s royalty surge, you know the challenge. Stock Titan solves this complexity by turning every Ligand disclosure—from the latest 8-K material event to its 250-page annual report—into concise insights you can act on.
Our platform ingests every document the moment it hits EDGAR and generates AI-powered summaries that explain the impact in plain English. Need the numbers behind the "Ligand Pharmaceuticals quarterly earnings report 10-Q filing"? We tag segment revenue, cash-flow swings, and Captisol sales automatically. Monitoring executives? Receive real-time alerts for "Ligand Pharmaceuticals insider trading Form 4 transactions" and spot buying or selling patterns before the market digests them. Whether you are comparing pipeline milestones across 10-K sections or verifying "Ligand Pharmaceuticals proxy statement executive compensation" details, the information is organized, searchable, and translated into clear language.
Here’s what you gain: instant context around royalty forecasts, AI commentary that demystifies complex licensing disclosures, and full coverage of every form—10-K, 10-Q, 8-K, S-8, and Form 4—delivered the moment Ligand files. Skip the manual page-flip: with Stock Titan you’re "understanding Ligand Pharmaceuticals SEC documents with AI" in minutes, tracking "Ligand Pharmaceuticals executive stock transactions Form 4" effortlessly, and turning dense reports into strategic decisions without losing valuable time.
Form 3/A filing for Ligand Pharmaceuticals Inc. (LGND) discloses an amended initial beneficial ownership statement for Chief Financial Officer Octavio Espinoza.
- Date of event: 11/01/2022 (original Form 3 date); amendment filed 07/02/2025.
- Shares owned: 1,696 shares of LGND common stock reported as directly held.
- Purpose of amendment: Corrects the original Form 3, which inadvertently understated Mr. Espinoza’s direct holdings by exactly 1,696 shares. The correction also updates related Form 4 reports filed through the amendment date.
- Reporting person’s role: Officer – Chief Financial Officer.
No derivative securities are reported, and there are no other changes to ownership structure, relationships, or control disclosed in this filing.
Form 4 Filing Details: Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals (LGND), reported a sale of 500 shares of common stock on June 23, 2025, at an average price of $114.0843 per share.
Following the transaction, Reardon continues to hold 31,903 shares directly. The sale represents approximately 1.5% of his direct holdings. The transaction was reported within the required two-business-day filing deadline, with the Form 4 being filed on June 24, 2025.
This insider sale occurs at a time when LGND executives must comply with SEC regulations regarding insider trading. The filing indicates this was a direct ownership transaction, and no derivative securities were involved in this report.
FAQ
What is the current stock price of Ligand Pharma (LGND)?
What is the market cap of Ligand Pharma (LGND)?
